CRDMO

Jubilant Biosys offers a comprehensive range of CRDMO services to help accelerate drug discovery programs across therapeutic areas including oncology, pain & inflammation, CNS and metabolism. Talk to our experts to find out how our cross-functional teams of more than 1200 experts can support you, from early discovery to commercial supply.

Delivering excellence

Across the Drug Discovery value chain

A team of 1200+ experts, led by more than 70 PhDs with EU and US experience tackle complex challenges across integrated drug discovery, chemistry and biology, delivering both end-to-end and ad hoc solutions. We serve our customers and partners through flexible engagement models from four locations across India.

Talk to our experts

From early discovery to commercial supply

Solving target and hit challenges

• Fragment & library synthesis
• Assays & reagents
• Native ligands
• Tool compounds
• Screenings

Solving molecular design challenges

• High Resolution Mass Spectroscopy (HRMS)
• X-ray Crystallography
• Iterative synthesis-test-design
• Lead Optimization

Solving DMPK and toxicology challenges

• In-vitro Physiochemistry
• Metabolism
• Permeability
• In-vivo tissue distribution
• Animal Pharmacokinetics
• Excretion studies

Solving scale-up & manufacturing challenges

• Route scouting
• Process development
• CMC & GMP support
• IND filing support
• API sourcing
• Bulk manufacturing
• Technology transfer (if needed)

From early discovery to commercial supply

Name*

Email*

—Please choose an option—Discovery ChemistryDiscovery BiologyIntegrated Drug DiscoveryCDMODigital Services*

Company-Name*

—Please choose an option—ArubaAfghanistanAngolaAlbaniaAndorraUnited Arab EmiratesArgentinaArmeniaAmerican SamoaAntigua and BarbudaAustraliaAustriaAzerbaijanBurundiBelgiumBeninBurkina FasoBangladeshBulgariaBahrainBahamasBosnia and HerzegovinaBelarusBelizeBermudaBolivia, Plurinational State ofBrazilBarbadosBrunei DarussalamBhutanBotswanaCentral African RepublicCanadaSwitzerlandChileChinaCôte d'IvoireCameroonCongo, Democratic Republic of theCongoCook IslandsColombiaComorosCabo VerdeCosta RicaCubaCayman IslandsCyprusCzechiaGermanyDjiboutiDominicaDenmarkDominican RepublicAlgeriaEcuadorEgyptEritreaSpainEstoniaEthiopiaFinlandFijiFranceMicronesia, Federated States ofGabonUnited Kingdom of Great Britain and Northern IrelandGeorgiaGhanaGuineaGambiaGuinea-BissauEquatorial GuineaGreeceGrenadaGuatemalaGuamGuyanaHong KongHondurasCroatiaHaitiHungaryIndonesiaIndiaIrelandIran, Islamic Republic ofIraqIcelandIsraelItalyJamaicaJordanJapanKazakhstanKenyaKyrgyzstanCambodiaKiribatiSaint Kitts and NevisKorea, Republic ofKuwaitLao People's Democratic RepublicLebanonLiberiaLibyaSaint LuciaLiechtensteinSri LankaLesothoLithuaniaLuxembourgLatviaMoroccoMonacoMoldova, Republic ofMadagascarMaldivesMexicoMarshall IslandsNorth MacedoniaMaliMaltaMyanmarMontenegroMongoliaMozambiqueMauritaniaMauritiusMalawiMalaysiaNamibiaNigerNigeriaNicaraguaNetherlands, Kingdom of theNorwayNepalNauruNew ZealandOmanPakistanPanamaPeruPhilippinesPalauPapua New GuineaPolandPuerto RicoKorea, Democratic People's Republic ofPortugalParaguayPalestine, State ofQatarRomaniaRussian FederationRwandaSaudi ArabiaSudanSenegalSingaporeSolomon IslandsSierra LeoneEl SalvadorSan MarinoSomaliaSerbiaSouth SudanSao Tome and PrincipeSurinameSlovakiaSloveniaSwedenEswatiniSeychellesSyrian Arab RepublicChadTogoThailandTajikistanTurkmenistanTimor-LesteTongaTrinidad and TobagoTunisiaTürkiyeTuvaluTaiwan, Province of ChinaTanzania, United Republic ofUgandaUkraineUruguayUnited States of AmericaUzbekistanSaint Vincent and the GrenadinesVenezuela, Bolivarian Republic ofVirgin Islands, BritishVirgin Islands, U.S.Viet NamVanuatuSamoaYemenSouth AfricaZambiaZimbabwe I am in*

Comment

Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders

Accelerating Drug Discovery Leveraging the Orbitrap HRMS for met-ID & large molecule analysis

Current Research in Pharmacology and Drug Discovery